Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: Results from a prospective, multicenter study

Oncology

Volumn 71, Issue 5-6, 2007, Pages 374-381

  Cazzaniga, Marina E ^a   Dogliotti, Luigi ^b   Cascinu, Stefano ^c   Barni, Sandro ^a   Labianca, Roberto ^d   Chiara, Silvana ^e   Conte, Pier Franco ^f   Gasparini, Giampietro ^g   Pasetto, Lara ^h   Torri, Valter ⁱ  

^a TREVIGLIO HOSPITAL   (Italy)

^b University at Orbassano   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g SAN FILIPPO NERI HOSPITAL   (Italy)

^h UNIVERSITY HOSPITAL OF PADOVA   (Italy)

ⁱ MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Bisphosphonates; Bone metastases; Breast cancer; Chemotherapy; Hormone therapy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PAMIDRONIC ACID; STEROID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; ITALY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DIPHOSPHONATES; DISEASE PROGRESSION; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 35348852218     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107772     Document Type: Article

References (20)

1. Galasko CSB: The anatomy and pathways of skeletal metastases; in Weiss L, Gilbert AH (eds): Bone Metastases. Boston, GK Hall, 1981, pp 49-63.
2. Tubiana-Hulin M: Incidence, prevalence and distribution of bone metastases. Bone 1991;12(suppl 1):9-10.
3. Rubens RD, Coleman RE: Bone metastases; in Albertoff MD, Armitage JO, Lichter AS, et al. (eds): Clinical Oncology, New York, Churchill Livingstone, 1995, pp 643-665.
4. Coleman RE, Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-66.
5. Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with advanced breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-1791.
6. Paterson AHG, Powels TJ, Kanis JA, et al: Double blind controlled trial of clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
7. Official Italian Census 2001. Rome, ISTAT, 2002.
8. Dancey J, Zee B, Osoba D, et al: Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. Qual Life Res 1997;6:151-158.
9. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD: A note on competing risks in survival data analysis. Br J Cancer 2004;91:1229-1235.
10. Coleman RE, Smith P, Rubens RD: Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998;78:336-340.
11. James JJ, Evans AJ, Pinder SE: Bone metastases from breast carcinoma: histopathological-radiological correlations and prognostic factors. Br J Cancer 2003;89:660-665.
12. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-942.
13. Koizumi M, Yoshimoto M, Kasumi F, et al: Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 2003;14:1234-1240.
14. Boxer DI, Todd CE, Fogelman I: Bone secondaries in breast cancer: the solitary metastasis. J Nucl Med 1989;30:1318-1320.
15. American Society of Clinical Oncology: Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996;14:671-679.
16. Cazzaniga ME, Pronzato P, Leto S: Patterns of relapse and modalities of treatment of breast cancer: the 'IRIS' project, a multicentre observational study. Oncology 2004;66:260-268.
17. Hillner BE, Ingle JN, Berenson JR: American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 2000;18:1378-1391.
18. Hortobagyi GN, Theriault RL, Lipton A: Long term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998;16:2038-2044.
19. Theriault RL, Lipton A, Hortobagyi GN: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized placebo-controlled trial. J Clin Oncol 1999;17:846-854.
20. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243-6249.